enGene Cuts Half Its Workforce as C-Suite Dissolves Before BLA
Distressed
Company Background
enGene Therapeutics is a clinical-stage gene therapy company whose pipeline is built around a single lead asset, detalimogene, currently being evaluated in the LEGEND pivotal trial. The company has no approved products and no product revenue; its path to commercial viability runs through regulatory approval of detalimogene. At approximately $115 million in market capitalization, enGene has limited financial cushion relative to the costs of late-stage drug development and the regulatory process ahead.
The twelve months prior to June 2026 produced no major catalysts or disclosed setbacks — the only notable corporate event was a routine Annual General Meeting on June 9, 2026, at which shareholders re-elected four directors, including CEO Ronald Cooper. There was no prior public signal of a restructuring.
What Was Disclosed
The board approved a roughly 50% workforce reduction on June 14, 2026, explicitly to "preserve shareholder capital as the Company awaits additional durability data and meetings with the Food and Drug Administration in connection with the Company's LEGEND pivotal cohort." Total estimated charges run from $10.4 million to $15.9 million: $5.7 million to $6.4 million in cash severance and benefits; $4.7 million to $5.0 million in non-cash expense from accelerated vesting of existing options; up to $1.7 million in cash performance retention awards; and up to $2.8 million in non-cash expense tied to new performance equity retention awards. The majority of these charges are expected to land in the second half of 2026.